Amgen
 
4Q Revenues: $4.4 billion (+11%)

4Q Earnings: $788 million (-16%)

YTD Revenues: $17.3 billion (+11%)

YTD Earnings: $4.3 billion (+18%)

Comments: Growth in the quarter was driven by sales of Enbrel (+23% to $1.2 billion), XGEVA (+7% to $215 million), and Prolia (+40% to $154 million). Combined Neulasta and Neupogen sales were down 1% in the quarter to $1.3 billion. Aranesp sales were down 9% to $489 million due to changes in practice patterns. EPOGEN sales were $479 million, down 1% due to a reduction in dose utilization. Sensipar/Mimpara sales increased 19% to $256 million in the quarter. Vectibix and Nplate sales increased 15% to $91 million and $101 million, respectively.